Vigabatrin vs Ethosuximide — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Anti-epileptic Agent

Vigabatrin

Brand: SABRIL

First FDA approval: 2009-08-21

Anti-epileptic Agent

Ethosuximide

Brand: Zarontin

First FDA approval: 2000-09-22

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$0.092Per unit

Average NADACAcross all dosage forms and strengths

—

$0.331Up to $1.31

Generic manufacturersActive ANDA holders — FDA Orange Book

1618 total ANDAs filed

88 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$43.0MFull year

$2.3MFull year

Part D claims (CY24)Total fills, all strengths

2K307 beneficiaries

24K4K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$18,374Per claim, all NDCs

$98Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

1078Substantial friction

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

5Limited friction

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

Yes16 manufacturers

Yes8 manufacturers